Cohen & Steers Inc. (CNS)
| Bid | 81.37 |
| Market Cap | 4.37B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 2.97 |
| PE Ratio (ttm) | 29.12 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 90.9 |
| Volume | 108,432 |
| Avg. Volume (20D) | 185,986 |
| Open | 86.30 |
| Previous Close | 86.41 |
| Day's Range | 85.45 - 86.98 |
| 52-Week Range | 64.13 - 110.67 |
| Beta | undefined |
About CNS
Cohen & Steers, Inc. is a publicly owned asset management holding company. Through its subsidiaries, the firm provides its services to institutional investors, including pension funds, endowments, and foundations. It manages separate client-focused equity, fixed income, multi-asset, and commodity portfolios through its subsidiaries. The firm launches and manages equity, fixed income, balanced, and multi-asset mutual funds through its subsidiaries...
Analyst Forecast
According to 2 analyst ratings, the average rating for CNS stock is "Buy." The 12-month stock price forecast is $106.5, which is an increase of 23.12% from the latest price.
Next Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
3 days ago · accessnewswire.com
CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development SummitHOUSTON, TX / ACCESS Newswire / February 18, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments fo...
1 week ago · accessnewswire.com
CNS Pharmaceuticals to Present at the BIO CEO & Investor ConferenceIn-person presentation today, February 10th at 1:15 PM ET HOUSTON, TX / ACCESS Newswire / February 10, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical co...
